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Abstract
Fanconi anaemia (FA) is a recessive autosomal disease determined by mutations in genes of at least eleven
complementation groups, with distinct distributions in different populations. As far as we know, there are no reports
regarding the molecular characterisation of the disease in unselected FA patients in Brazil. Objective: This study
aimed to investigate the most prevalent mutations of FANCA and FANCC genes in Brazilian patients with FA.
Methods: Genomic DNA obtained from 22 racially and ethnically diverse unrelated FA patients (mean age ± SD:
14.0 ± 7.8 years; 10 male, 12 female; 14 white, 8 black) was analysed by polymerase chain reaction and restriction
site assays for identification of FANCA (∆3788-3790) and FANCC (∆322G, IVS4+4A → T, W22X, L496R, R548X,
Q13X, R185X, and L554P) gene mutations. Results: Mutations in FANCA and FANCC genes were identified in 6
(27.3%) and 14 (63.6%) out of 22 patients, respectively. The disease could not be attributed to the tested mutations
in the two remaining patients enrolled in the study (9.1%). The registry of the two most prevalent gene abnormalities
(∆3788-3790 and IVS4 + 4 → T) revealed that they were present in 18.2% and 15.9% of the FA alleles, respectively.
Additional FANCC gene mutations were found in the study, with the following prevalence: ∆322G (11.4%), W22X
(9.1%), Q13X (2.3%), L554P (2.3%), and R548X (2.3%) of total FA alleles. Conclusion: These results suggest that
mutations of FANCA and FANCC genes are the most prevalent mutations among FA patients in Brazil.
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Introduction
Fanconi anaemia (FA) is an autosomal recessive dis-
ease characterised by a very high frequency of bone mar-
row failure and many other manifestations, including but
not restricted to severe birth defects and marked predisposi-
tion to malignancies, especially acute myeloid leukaemia
and, to a lesser extent, solid tumours (Young and Alter,
1994; Alter and Young, 1998; Alter, 2003).
FA cells exhibit spontaneous chromosomal instabil-
ity and hypersensitivity to DNA cross-linking agents such
as diepoxybutane (DEB) and mitomycin C (Auerbach and
Wolman, 1976) and the resulting increase in chromosome
breakage provides the basis for a diagnostic test (Auerbach,
1993).
Complementation analysis by cell fusion and correc-
tion of cross-linker hypersensitivity has delineated at least
eleven complementation groups (A, B, C, D1, D2, E, F, G,
L, I, J) (Joenje and Patel, 2001; Meetei et al., 2003) and
seven genes have been cloned (FANCA, C, D2, E, F, G and
L) (Strathdee et al., 1992; Whitney et al., 1993; Lo Tem Foe
et al., 1996; De Winter et al., 1998; De Winter et al., 2000;
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Timmers et al., 2001; Meetei et al., 2003). Four FA-D1 pa-
tients were shown to possess biallelic mutations in the
breast cancer susceptibility gene BRCA2 (Levitus et al.,
2003). FANCA and FANCC mutations are the most preva-
lent, accounting for approximately 65% and 5-15% of FA
patients (Tischkowitz and Hodgson, 2003).
The prevalence of distinct FA gene mutations is vari-
able in different populations (Tischkowitz and Hodgson,
2003). FANCA mutations are more common in Afrikaners
(Tipping et al., 2001) and FANC in Ashkenazi Jews and
Japanese (Yamashita et al., 1996; Gillio et al., 1997; Futaki
et al., 2000; Tamary et al., 2003).
The relationship between the complementation group
and mutation type and the clinical outcome of the patients
with disease is controversial. Patients with FANCA and
FANCG mutations appear to constitute a high risk group
according to some authors (Faivre et al., 2000). In contrast,
The International Fanconi Anaemia Register revealed a sig-
nificantly earlier onset of bone marrow failure and poorer
survival rates for complementation group C compared with
groups A and G. Moreover, there was no significant differ-
ence in the time for haematologic or nonhaematologic neo-
plasm development between FA groups of patients (Kutler
et al., 2003).
The ethnic origin of the Brazilian population is highly
heterogeneous, consisting of indigenous Amerindians and
immigrants from Europe, Africa, and Asia (Alves-Silva et
al., 2000; Carvalho-Silva et al., 2001).
The ∆3788-3790 and IVS8-2A > G gene mutations
were found in a group of Brazilian FA patients seen at a sin-
gle bone marrow transplantation service, and were de-
scribed as the most common FANCA and FANCG Brazilian
mutations by the International Fanconi Anemia Registry
(IFAR) (Levran et al., 1997; Auerbach et al., 2003). As far
as we know, there are no reports regarding the molecular
analysis of FA in unselected populations of our country.
Therefore, this was the aim of the study presented herein.
Material and Methods
Eligibility requirements
All unrelated patients with confirmed FA, attended at
the Medical Genetic and the Haematology services of
UNICAMP and Haemotherapy Centres of several Brazilian
Universities, were considered as fully eligible for the pres-
ent study. The diagnosis of the disease was based on clini-
cal and laboratory data, including haematological analysis,
bone marrow aspiration and biopsy, and was confirmed by
DEB test. The study protocol was approved by the local Re-
search Ethics Committee.
DEB test
TheDEB test was performed at the Cytogenetics Lab-
oratory of the Haematology and Haemotherapy Centre of
the State University of Campinas, according to conven-
tional methods (Rosendorff and Bernstein, 1988; Auerbach
et al., 1989).
Molecular Analysis of FANCA and FANCC genes
Genomic DNA was obtained from peripheral blood
of patients enrolled in the study using the salt/chloroform
method (Müllenbach et al., 1989). FANCA and FANCC
mutations were analysed by polymerase chain reaction
(PCR) followed by restriction site assays.
FANCA and FANCC exonic sequences of interest
were amplified by PCR using primers described by Levran
et al. (1997) and Gibson et al. (1996). PCR was carried out
in 25 µL reactions with 250 ng of genomic DNA, 10 ng/µL
of each primer, 0.5 mM of each dNTP, and 1.5 units of Taq
polymerase in a buffer containing 6.7 mM MgCl2. After
initial denaturation at 94 °C for 5 min, samples were ampli-
fied for 30 denaturation cycles at 94 °C for 1 min, annealing
at 51-60 °C, and extension at 72 °C for 1 min, followed by a
final 5 min extension at 72 °C.
PCR products were then digested with 5-10 units of
the appropriate restriction enzyme for a minimum of 2 h at
37 °C (50C for Bcl I), according to previously described
techniques (Gibson et al., 1996; Levran et al., 1997) and
analysed on horizontal 7% polyacrylamide gel.
The investigated gene mutations, restriction en-
zymes, and sizes of the normal and mutant gene fragments
obtained from PCR and restriction site assays performed in
the study are presented in Table 1.
Results
The clinical and laboratory features of 22 FA patients
enrolled in the study are presented in Table 2. Their mean
age ± SD was 14.0 ± 7.8 years (range: 2-33 years); 10 pa-
tients were male and 12 female, 14 were white and 8 black.
Sixteen patients presented congenital abnormalities such as
microphthalmia (8 cases), microcephaly (4 cases), abnor-
malities of the thumbs (5 cases), café-au-lait spots (4
cases), hyperpigmentation (4 cases), short stature (2 cases),
genital abnormalities (1 case), and renal aplasia (1 case).
Short stature was the only physical abnormality identified
in FANCA patients. Variable degrees of peripheral
cytopenia and positive DEB test were found in all patients
enrolled in the study. Cases 1, 2, 16 and 22 are children of
consanguineous parents (18%).
FA was attributed to ∆3788-3790 mutation of the
FANCA gene in 6 out of 22 (27.3%) patients. The gene ab-
normality was present in 18.2% of FA alleles. Mutations of
the FANCC gene were found in 14 out of 22 (63.6%) pa-
tients, with the following prevalence: 15.9% for IVS4+4A
→ T, 11.4% for ∆G322, 9.1% for W22X, 2.3% for Q13X,
2.3% for L554P, and 2.3% for R548X on FA alleles. The
analysed mutations were not found in 2 out of 22 (9.1%) pa-
tients enrolled in the study. Figure 1 shows the analysis for
IVS4+4A → T mutation.
206 Rodriguez et al.
Two pre-symptomatic patients with FA were identi-
fied in our familial studies (Cases 1 and 2).
Discussion
We have screened the ∆3788-3790 mutation of the
FANCA and eight mutations (IVS4+4 A → T, ∆G322,
W22X, Q13X, L554P, R548X, L496R, and R185X) of the
FANCC genes in an unselected group of Brazilian patients
with confirmed FA diagnosis.
The median age of the studied group, 14 years old,
was higher than those obtained in previous reports, which
was 7 years old (McMullin et al., 1991; Auerbach and Al-
len, 1994; Butturini et al., 1994), and may be attributed to
the difficulties in achieving a reference service for FA diag-
nosis in the country. The congenital abnormalities were
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Table 1 - Fragments observed after digestion with respective restriction enzymes for the distinct analysed mutations in Fanconi anaemia patients.
Mutation Gene Restriction enzyme Result of PCR Normal fragments Mutant fragments
∆3788-3790 FANCA MboII 160 bp 130 + 30 160
IVS4+4A → T FANCC Sca I 131 bp 108 + 23 131
∆G322 FANCC Bsp1286 I 151 bp 129 + 22 152
W22X FANCC FoK I 221 bp 204 + 17 187 + 17 + 17
Q13X FANCC Bcl I 250 bp 227 + 23 250
L554P FANCC Bbv I 364 bp 260 + 104 364
R548X FANCC Ava I 364 bp 231 + 133 364
L496R FANCC Hha I 303 bp 303 218 + 85
R185X FANCC Nla III 122 bp 105 + 17 74 + 31 + 17
PCR, polymerase chain reaction; bp, base pairs.
Table 2 - Clinical and molecular features of 22 patients with Fanconi anaemia.
Case Age (years) Gender Race Abnormal gene Genotype
1 28 Female White FANCA ∆3788-3790 / ∆3788-3790
2 23 Female Black FANCA ∆3788-3790 / ∆3788-3790
3 8 Male White FANCA ∆3788-3790 / NI
4 6 Male White FANCA ∆3788-3790 / NI
5 15 Female White FANCA ∆3788-3790 / NI
6 10 Female White FANCA ∆3788-3790 / NI
7 18 Male White FANCC IVS4 + 4 A → T / ∆G322
8 10 Female White FANCC IVS4 + 4 A → T / ∆G322
9 12 Male White FANCC IVS4 + 4 A → T / ∆G322
10 8 Male White FANCC IVS4 + 4 A → T / NI
11 18 Male Black FANCC IVS4 + 4 A → T / NI
12 15 Female Black FANCC IVS4 + 4 A → T / NI
13 20 Female Black FANCC IVS4 + 4 A → T / NI
14 18 Female Black FANCC ∆G322 / NI
15 14 Male White FANCC ∆G322 / W22X
16 14 Male White FANCC W22X/W22X
17 2 Male White FANCC W22X/ NI
18 33 Female White FANCC Q13X / NI
19 19 Female Black FANCC L554P / NI
20 5 Male Black FANCC R548X/ NI
21 10 Female White NI NI / NI
22 3 Female Black NI NI / NI
NI, not identified.
more frequent and severe in FA determined by FANCC
gene mutations, particularly in cases with IVS4+4 A → T
mutations, in accordance with previous reports (Faivre et
al., 2000).
Interestingly, the disease was found in 8 (36.4%) pa-
tients of African origin in our group, in disagreement with
the reports of Rosendorff et al. (1987) and MacDougall et
al. (1990), in which the disease was rare in this race.
Mutations in the FANCC and FANCA genes ac-
counted for approximately two-thirds and one-third of our
cases. The disease was not determined by the tested muta-
tions in only 9.1% of analysed cases. Therefore, FANCC
gene mutations were the most prevalent in our group of pa-
tients (14 patients), in disagreement with previous reports
that show to a higher prevalence of FANCA mutations in
the majority of populations (Tischkowitz and Hodgson,
2003).
Levran et al. (1997) and Auerbach et al. (2003) de-
scribed the ∆3788-3790 and IVS8-2A > G as the most com-
mon Brazilian mutations of FANCA and FANCC genes. As
far as we know, both studies included Brazilian patients
from a single bone marrow transplantation service, and
may have included predominantly patients with the most
severe disease forms. In our sample there were both pa-
tients with slight and severe haematological manifesta-
tions. As we did not select patients for study, it is possible
that mutations of the FANCC gene represent a particular
characteristic of the Brazilian population.
The most prevalent mutation of FANCA gene in our
group was ∆3788-3790, in accordance with the report by
Levran et al. (1997). The second most common mutation
was the IVS4+4 A → T of the FANCC gene (Yamashita et
al., 1996; Gillio et al., 1997; Tamary et al., 2003).
In addition, the molecular analysis performed in our
study was also important for early diagnosis of the disease,
identification of pre-symptomatic and unaffected siblings
with FA, as well as genetic counselling for the family.
Another fact that draws our attention is the high num-
ber of compound heterozygotes among FA patients. Since
FA is considered a rare disease, a high rate of consanguine-
ous parents and a larger number of homozygotes was ex-
pected, but not found in study. Our data suggest that FA
may not be as rare as thought and taking into account its
variable expressivity, many cases may be undiagnosed.
In conclusion, these results present preliminary evi-
dence that FANCA and FANCC gene mutations are the
most prevalent mutations among Brazilian FA patients.
However, a large study concerning the molecular analysis
of the Brazilian FA patients from different areas of the
country should be carried out to clarify this issue.
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